Skip to content

Lymphoscintigraphy Combine Staining in Diagnose of Internal Mammary Sentinel Lymph Nodes of Breast Cancer: A Pilot Clinical Study

Lymphoscintigraphy Combine Staining in Diagnose of Internal Mammary Sentinel Lymph Nodes of Breast Cancer: A Pilot Clinical Study

Status
Active, not recruiting
Phases
Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-DCC-11001733
Enrollment
Unknown
Registered
2011-11-28
Start date
2010-06-24
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

Gold Standard:
Index test:

Sponsors

Southwest Hospital, Third Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. invasive breast cancer is confirmed by preoperative hollow needle aspiration biopsy; 2. the tumor is unilateral, single; 3. preoperative chest radiograph, abdominal ultrasound and systematic bone scan confirmed no metastases in lung, liver or bone, if necessary, additional chest or abdominal CT or MRI should be taken; 4. tumor is located in the central, medial or lateral area; 5. tumor size >=5.0 cm; 6. ipsilateral ALN are swollen, confluenced with each other or adhered with other tissue; 7. clinical ultrasound, CT or MRI shows remarkable IMN metastasis; 8. neoadjuvant chemotherapy for 2-4 courses before surgery; 9. no malignant tumor located in other sites of body.

Exclusion criteria

Exclusion criteria: 1. with serious cardiac or pulmonary diseases, unable to tolerate the operation; 2. with pleura adhesion or lung adhesion or case history of thoracic operation; 3. inflammatory breast cancer; 4. breast cancer in pregnancy or lactation; 5. chemotherapy history in breast area.

Design outcomes

Primary

MeasureTime frame
Internal mammary sentinel lymph node detection rate;

Countries

China

Contacts

Public ContactJun Jiang
jcbd@medmail.com.cn+86 023 68765633

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026